A significant part of her Estrogen receptor research incorporates Progesterone receptor and Fulvestrant studies. Nadia Harbeck performs integrative study on Fulvestrant and Palbociclib in her works. Nadia Harbeck's looking at Metastasis as part of her Primary tumor and Intravasation and Metastasis study. Many of her studies on Internal medicine involve topics that are commonly interrelated, such as Consensus conference. Her research brings together the fields of Sentinel node and Cancer. Borrowing concepts from Radiation therapy, Nadia Harbeck weaves in ideas under Oncology. Nadia Harbeck carries out multidisciplinary research, doing studies in Radiation therapy and Adjuvant therapy. In her works, Nadia Harbeck performs multidisciplinary study on Adjuvant therapy and Neoadjuvant therapy. She carries out multidisciplinary research, doing studies in Breast cancer and Triple-negative breast cancer.
Her study on Internal medicine is mostly dedicated to connecting different topics, such as Consensus conference. She merges Cancer with Surgery in her research. With her scientific publications, her incorporates both Surgery and Cancer. Nadia Harbeck undertakes multidisciplinary investigations into Oncology and Chemotherapy in her work. In her research, she performs multidisciplinary study on Chemotherapy and Breast cancer. Her work blends Gynecology and Pathology studies together. Nadia Harbeck conducts interdisciplinary study in the fields of Pathology and Gynecology through her works. Her Adjuvant study frequently links to other fields, such as Oncology. In her works, she performs multidisciplinary study on Cancer research and Metastasis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith;Marion Procter;Richard D Gelber;Sébastien Guillaume.
The Lancet (2007)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn;Miguel Martin;Hope S. Rugo;Stephen Jones.
The New England Journal of Medicine (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro.
Lancet Oncology (2016)
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
Nicholas C. Turner;Jungsil Ro;Fabrice André;Sherene Loi.
The New England Journal of Medicine (2015)
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
David W. Miles;Arlene Chan;Luc Y. Dirix;Javier Cortés.
Journal of Clinical Oncology (2010)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant.
Annals of Oncology (2017)
Pembrolizumab for Early Triple-Negative Breast Cancer.
Peter Schmid;Javier Cortes;Lajos Pusztai;Heather McArthur.
The New England Journal of Medicine (2020)
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Maxime P. Look;Wim L. J. van Putten;Michael J. Duffy;Nadia Harbeck.
Journal of the National Cancer Institute (2002)
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
F. Cardoso;A. Costa;L. Norton;E. Senkus.
Annals of Oncology (2014)
Triple-negative breast cancer—current status and future directions
O. Gluz;C. Liedtke;N. Gottschalk;L. Pusztai.
Annals of Oncology (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: